ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models

Cramer, Paige E., Cirrito, John R., Wesson, Daniel W., Lee, C. Y. Daniel, Karlo, J. Colleen, Zinn, Adriana E., Casali, Brad T., Restivo, Jessica L., Goebel, Whitney D., James, Michael J., Brunden, Kurt R., Wilson, Donald A., Landreth, Gary E.·2012·Science
DOI 10.1126/science.1217697

Cited by (1,000)

Items 901–1,000 of 1,000

  1. Analytical methods for bexarotene determination: a comparative review of chromatographic techniques through the lens of green chemistry
    Kanaka Parvathi Kannaiah, Hemraj Sharma, Hemanth Kumar Chanduluru, Rita Keshishian, Reem Hasan Obaydo · 2026 · Green Chemistry Letters and Reviews
  2. 1α,25-Dihydroxyvitamin D3 and Resolvins Improve Immunity to Amyloid-β in Patients with Alzheimer’s Disease
    Milan Fiala, Rachel E. Weitzman · 2014 · Elsevier eBooks
  3. Rational design and virtual screening identify mimetics of the RXR agonist valerenic acid
    Laura Isigkeit, Annette Kärcher, Gustave Adouvi, Silvia Arifi, Daniel Merk · 2024 · ChemMedChem
  4. Bexarotene Induce Differentiation of Myeloid-Derived Suppressor Cells through Arg-1 Signalling Pathway
    Haozhou Wang, Yinan Guo, Xiaodong Zhang, Xiaoguang Zhou · 2024 · Transplantation Proceedings
  5. Activation of retinoid X receptors protects retinal neurons and pigment epithelial cells from BMAA-induced death
    Tamara B. Soto, Paula Estefanía Tenconi, Edgardo D. Buzzi, Leonardo Dionisio, Melina V. Mateos, Nora P. Rotstein, Guillermo F. Spitzmaul, Luis E. Politi, Olga Lorena German · 2024 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  6. Dementia-Related Features in Longitudinal MRI: Tracking Keypoints over Time
    Elisabeth Stühler, Michael R. Berthold · 2014 · Lecture notes in computer science
  7. Brain Single-Cell Transcriptional Responses to Bexarotene-Activated RXR in an Alzheimer’s Disease Model
    Carolina Saibro Girardi, Lu Yi, Nicholas Francis Fitz, Daniel Pens Gelain, Iliya M. Lefterov, Radosveta P. Koldamova · 2026 · International Journal of Molecular Sciences
  8. Computational Drug Discovery in Patients with Endometriosis-Induced Infertility via Text Mining and Biomedical Databases
    Yingying Lin, Zhiwei Chen, Jianping Huang, Jiaoning Fang, Yuanjie Qi, Li Huitong Xie, Hua Li, Li Chen · 2022 · Clinical and Experimental Obstetrics & Gynecology
  9. Worming Our Way to Alzheimer’s Disease Drug Discovery
    Sangeetha V. Iyer, Jonathan T. Pierce-Shimomura · 2013 · Biological Psychiatry
  10. Therapeutic Links between Alzheimer’s Disease and Brain Cancer: Drug Discovery Consequences
    Jean‐Louis Kraus · 2013 · ChemMedChem
  11. The Relationship Between Astrocyte-mediated Metabolism of β-Amyloid Protein and Pathogenesis of The Early Stages of Alzheimer′s Disease*
    Lu yi Lin, Shujun Xu, Qinwen Wang · 2012 · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
  12. Contemporary Approaches for Pharmacological Intervention of Abundant Neurodegenerative Disorders
    Сергей Олегович Бачурин · 2015 · Journal of Nanomedicine & Biotherapeutic Discovery
  13. Hypothesis: Entrapment of lipoprotein particles in the brain causes Alzheimer’s disease
    Delphine Boche, James A. R. Nicoll · 2021 · Free Neuropathology
  14. Tracking the insidious course of Alzheimer's disease
    2012 · Nature Medicine
  15. Navigating the Landscape of Alzheimer's Disease: From Epidemiology to Drug Re-purposing
    Karishma Rathi, Ritesh P. Bhole, Prachi Bansode, Nayan Motghare · 2024 · Advances in Pharmacology and Pharmacy
  16. Molecular Basis of Neurodegeneration: Lessons from Alzheimer’s and Parkinson’s Diseases
    Juan Manuel Zolezzi, Sussy Bastias Candia, Nibaldo C. Inestrosa · 2019 · IntechOpen eBooks
  17. Fluorine-18 (18F)-labeled retinoid x receptor (RXR) partial agonist whose tissue transferability is affected by other RXR ligands
    Yuta Takamura, Osamu Shibahara, Masaki Watanabe, Michiko Fujihara, Shoya Yamada, Masaru Akehi, Takanori Sasaki, Hiroyuki Hirano, Hiroki Kakuta · 2019 · Bioorganic & Medicinal Chemistry
  18. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN
    Peter W. Jurutka, Carl E. Wagner · 2019 · Methods in molecular biology
  19. Studies cast doubt on cancer drug as Alzheimer's treatment
    Helen M. Shen · 2013 · Nature
  20. Alternative activation
    Kristen S. Young, Sean William Fanning · 2023 · eLife
  21. Why freshwater hydra does not get Alzheimer’s disease
    Alexander N. Khokhlov · 2023 · Vestnik Moskovskogo universiteta Seria 16 Biologia
  22. Potential treatment of Alzheimer’s disease astrocyte pathology based on nuclear lipid regulation
    Masato Komai, Nobumasa Takasugi · 2024 · Neural Regeneration Research
  23. Protein misfolding and neurodegeneration: Mechanisms, implications, and therapeutic strategies
    Asma Shah, Tharini Karthikeyan, Sheema Hashem, Rakesh Kumar, Ajaz Ahmad Bhat, Muzafar Ahmad Macha · 2025 · Advances in protein chemistry and structural biology
  24. An Iodinated BODIPY-Based Probe for the Selective Mapping and Disassembly of Amyloid-β Aggregates In Vivo
    Mingguang Zhu, Lijun Ma, Ran Liu, Fanghui Liang, Zixuan Zhang, Guoyang Zhang, Yulong Jin, Xuefei Wang, Zhuo Wang · 2026 · Analytical Chemistry
  25. Impact of Variation in APOE on Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Sequencing and Genotyping in General Population Cohorts
    Katrine Laura Rasmussen, Jiao Luo, S. Pors Nielsen, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen, Ruth Frikke‐Schmidt · 2026 · ACR Open Rheumatology
  26. Atherosclerosis and dementia - causal aspects and preventive potential
    Ida Juul Rasmussen, Jiao Luo, Katrine Laura Rasmussen, Emilie Westerlin Kjeldsen, Lucia Sanchez Schneider, Nicolai Sandau, Jesper Qvist Thomassen, Ruth Frikke‐Schmidt · 2026 · Atherosclerosis
  27. Apolipoprotein E in Alzheimer's disease: A review of APOE receptors, signalling pathways and therapeutic opportunities
    J. Saravanan, Vigneshwaran Easwaran, Divakar Selvaraj, Venkatesh Gunasekaran, V. Soumya, M. Thiruselvi, M. Laxmana Prasanth, Siddharth Singh, C. Ellaiyarasu, P. Karthik Rai et al. · 2026 · Molecular and Cellular Neuroscience
  28. Acitretin shows promising potential in Alzheimer’s disease: retinoid-driven modulation of amyloid processing, neuroinflammation, and translational prospects
    Varun Sharma, Kanika Vashisht, Garima Choudhary, Vaishali Choudhay, Vandana Bhatia, Mahendra Singh Ashawat, Ashish Baldi, Shiv Kumar Kushawaha · 2026 · Inflammopharmacology
  29. Does perturbed adaptive myelination contribute to cognitive dysfunction in Alzheimer’s disease?
    Charles ffrench‐Constant · 2026 · PLoS Biology
  30. Clearing away Alzheimer's disease
    Darran M. Yates · 2012 · Nature reviews. Neuroscience
  31. Translationale Forschung in der Geriatrie?
    Leo Cornelius Bollheimer, Dorothee Volkert, Tobias Bertsch, Jürgen Martin Bauer, Jochen Klucken, Cornel Christian Sieber, Reinhard Büttner · 2012 · Zeitschrift für Gerontologie und Geriatrie
  32. Evidence based computational drug repositioning candidate screening pipeline design: Case Study
    Qian Zhu, Hongfang Liu, Yuji Zhang, Jiabei Wang · 2014 · IEEE International Conference on Systems Biology
  33. Ausgewählte altersbedingte Erkrankungen
    Christian Behl, Christine Ziegler · 2015 · Springer eBooks
  34. Comprehensive Overview of Alzheimer’s Disease Neurodegeneration, from Amyloid-β to Neuroinflammatory Modulation
    Juan Manuel Zolezzi, Nibaldo C. Inestrosa · 2017 · InTech eBooks
  35. Time-Resolved In Situ AFM Measurement of Growth Rates of Aβ40 Fibrils
    Peter G. Vekilov, Peter Guy Wolynes · 2022 · Methods in molecular biology
  36. A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs
    Willy Smeralda, Marc Since, Sophie Corvaisier, Dimitri Fayolle, Julien Cardin, Sylvain Duprey, Jean‐Pierre Jourdan, Christophe Cullin, Aurélie Malzert‐Fréon · 2023 · International Journal of Molecular Sciences
  37. An Investigation of the Inflammatory Landscape in the Brain and Bone Marrow of the APP/PS1 Mouse
    Kishore Chittimalli, Stephen Adkins, Sanjay Arora, Jagdish Singh, Yagna P. R. Jarajapu · 2024 · Journal of Alzheimer s Disease Reports
  38. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration
    Suneela Sunil Dhaneshwar, Mohammad Aadil Bhat, Anuradha Singh, Supriya Roy · 2024 · BENTHAM SCIENCE PUBLISHERS eBooks
  39. Receptor agonist/antagonist-incorporated anticancer nanodrugs: Design, materials, and strategies
    Shi-Jie Hao, Shun‐Yu Wu, Yun-Kai Chang, Fu‐Gen Wu · 2024 · Materials Today
  40. Distinct functional modes of SUMOylation for retinoid X receptor alpha
    Wai-Ping Lee, Sarita Jena, Edna Patricia Rodriguez, Sinead P. O'Donovan, Carl E. Wagner, Peter W. Jurutka, Paul D. Thompson · 2015 · Biochemical and Biophysical Research Communications
  41. Advances in Therapies and Scope for Personalized Medicine in Alzheimer’s Disease
    Hosakere N Ravishankar, A. K. Dutta, Alisha G. Lewis, Amogh Mohan · 2016 · Personalized Medicine
  42. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN
    Carl E. Wagner, Peter W. Jurutka · 2019 · Methods in molecular biology
  43. The future of dementia prevention and treatment strategies
    里 直行 · 2020 · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics
  44. Radiopharmaceutical Discovery with 11CO2-Fixation Methods Inspired by Green Chemistry
    Benjamin H. Rotstein, Neil Vasdev · 2021 · Methods in pharmacology and toxicology
  45. Effects of C-Terminal-Ethyl-Esterification in a Snake-Venom-Based Peptide Against the Neurotoxicity of Acrolein in PC12 Cells
    Carolina Petri Bernardes, Neife Aparecida Guinaim dos Santos, Tássia R. Costa, Danilo L. Menaldo, F Sisti, Martin K. Amstalden, Diego Luís Ribeiro, Lusânia Maria Greggi Antunes, Suely Vilela Sampaio, Antonio Cardozo dos Santos · 2023 · International Journal of Peptide Research and Therapeutics
  46. PAK1 in Alzheimer’s and Huntington’s Diseases
    Qiu‐Lan Ma, Fusheng Yang, Sally Ann Frautschy, Greg M. Cole · 2013 · Elsevier eBooks
  47. The aging synapse: Synaptic proteome changes in mouse models of aging
    Marlene J. Végh · 2012 · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
  48. Bexarotene treatment does not clear β-Amyloid in an AD mouse model and Beagle dogs
    Ina C. Tesseur, Adrian C. Lo, Anouk Roberfroid, Sofie Dietvorst, Bianca Van Broeck, Marianne Borgers, Harrie J. M. Gijsen, Diederik Moechars, Marc H. Mercken, John A. Kemp et al. · 2013 · Molecular Neurodegeneration
  49. High Throughput Discovery, Metabolism and Disposition of Chemopreventive Agents using Mass Spectrometry
    Lian Chen · 2013 · Figshare
  50. Synaptic modifications in hippocampal CA3 pyramidal cells in an Alzheimer's mouse model
    Pei Zhang · 2018 · eDiss (Georg-August-Universität Göttingen)
  51. Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
    Steve Pedrini, Mike Morici, Ralph Nigel Martins · 2019 · Wiley eBooks
  52. Serum Metabolites Associated with Brain Amyloid Beta Deposition, Cognitive Dysfunction, and Alzheimer’s Disease Progression
    Kwangsik T. Nho, Alexandra Kueider‐Paisley, Matthias Arnold, Siamak MahmoudianDehkordi, Shannon L. Risacher, Gregory Louie, Colette Blach, Rebecca Baillie, Xianlin Han, Gabi Kastenmueller et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  53. BAC Transgenic Expression of Human TREM2-R47H Remodels Amyloid Plaques but Unable to Reprogram Plaque-associated Microglial Reactivity in 5xFAD Mice
    C.Y. Daniel Lee, Amberlene J. De La Rocha, Kellie Inouye, Peter Langfelder, Anthony Daggett, Xiaofeng Gu, Lu-Lin Jiang, Zoe Pamonag, Raymond Vaca, Jeffrey Richman et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  54. KOLF2.1J iTF-Microglia: A standardized platform to study microglial transcriptional regulatory networks in CNS disease
    Iván Rodríguez-Nunez, Samuel C. Bartley, Jared W. Taylor, S. Quinn Johnston, Brianne B. Rogers, Sarah Kristen Meadows, Kimberly M. Newberry, J. Nicholas Cochran, R Myers · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  55. Selected Age-Related Disorders
    Christian Behl, Christine Ziegler · 2013 · SpringerBriefs in molecular medicine
  56. Microglial involvement in brain physiopathology: in vitro studies using rat primary cultures
    Ilaria Mengoni · 2014 · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)
  57. Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
    Jacob M. Basak · 2014 · Open Scholarship Institutional Repository (Washington University in St. Louis)
  58. AZ goes APOE
    Lev Z. Osherovich · 2012 · Science-Business eXchange
  59. Amyloid‐Plaques – wie sie entstehen und wie man sie wieder los wird
    Michael Groß · 2012 · Chemie in unserer Zeit
  60. Probable Bexarotene Hepatotoxicity Associated With Transient Serum Antimitochondrial Antibodies
    Howard J. Worman · 2012 · Journal of Medical Cases
  61. Toll-erating AD
    Lev Z. Osherovich · 2013 · Science-Business eXchange
  62. 1 THE IMPACT OF RETINOIDS ON THE THYROID AXIS Running Head: RETINOIDS AND THYROID AXIS
    Julia Graeppi-Dulac · 2016
  63. Other Genes Implicated in Alzheimer’s Disease
    Minerva M. Carrasquillo, Mariet Allen, Nilüfer Ertekin‐Taner · 2013 · Springer eBooks
  64. Human APOE4 affects microglial reactivity and spatial cognition in a mouse model of alzheimer's disease risk
    Gustavo A. Rodriguez · 2014 · DigitalGeorgetown (Georgetown University Library)
  65. Apolipoprotein E and Mitochondria-associated Endoplasmic Reticulum Dysfunction
    Marc D. Tambini · 2016
  66. Cancer Drug Clears Amyloid Beta, Improves Behavior in Alzheimer Disease Mice
    Richard Robinson · 2012 · Neurology Today
  67. Review Article Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders
    Vijay K. Ramanan, Andrew J. Saykin · 2013
  68. Immune activation in Aβ-related angiitis (ABRA) and a cell model of E280A presenilin-mutated Familial Alzheimer's Disease
    Markus Glatzel · 2014
  69. Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
    Fan Liao, David M. Holtzman · 2016 · Elsevier eBooks
  70. Anti-platelet aggregation activity of melaleuca bracteata var.revolution gold derived betulinic acid and its derivatives
    Foluso Oluwagbemiga Osunsanmi · 2015
  71. Frontiers in Clinical Drug Research - Alzheimer Disorders
    Marei, Hany E., Althani, Asmaa, Suhonen, Jaana, El Zowalaty, Mohamed E., Albanna, Mohammad A., Cenciarelli, Carlo, Wang, Tengfei, Caceci, Thomas · 2016 · BENTHAM SCIENCE PUBLISHERS eBooks
  72. Deciphering the role of 27-hydroxycholesterol in neurodegeneration
    Muhammad Al Mustafa Ismail · 2016 · Figshare
  73. Drug Directed at ApoE Production is Successful in Mouse Models of Alzheimer Disease
    Anthony L. Komaroff · 2012 · Journal watch
  74. Proxy-PET Building Blocks as a Design Element for Library Synthesis
    Lainey Jo Mallin · 2015 · Journal of Bioresource Management
  75. Effect of liver x receptor target genes Apolipoprotein E and ATP-binding cassette transporter A1 on beta-amyloid dependent pathology in Alzheimer's disease model mice
    Alexis B. Carter · 2017 · D-Scholarship@Pitt (University of Pittsburgh)
  76. Amyloid-beta42 toxicity reduction in human neuroblastoma cells using cholera toxin b subunit-myelin basic protein expressed in chloroplasts
    Alexandra Ayache · 2012 · Journal of International Crisis and Risk Communication Research
  77. Association Between Blood Serum Antioxidant Status and Cognitive Function
    Karen Niemchick · 2017 · ScholarWorks (Walden University)
  78. Nitrate Chimeras: A New Class of Disease Modifying Agents for the Treatment of Alzheimer's Disease
    Lawren A. VandeVrede · 2014 · Figshare
  79. Cerebral Innate Immunity
    David Gate, Terrence Town · 2016 · Elsevier eBooks
  80. Metabolic study of Alzheimer’s disease using mutant C. elegans
    Waqar Ahmad · 2017 · The University of Queensland
  81. DEPLETION OF TDP-43 ACCELERATES NEURODEGENERATION IN AN ALZHEIMER’S MOUSE MODEL, INDEPENDENT OF BETA-AMYLOID PLAQUE BURDEN
    Katherine D. LaClair · 2016
  82. Conformational Fluctuations of Biomolecules Studied Using Molecular Dynamics and Enhanced Sampling
    Geoffrey Gray · 2018 · Digital Commons - University of South Florida (University of South Florida)
  83. Exposition aux organochlorés et démence dans la population âgée du Canada
    Thierry Comlan Marc Medehouenou · 2013
  84. The role of apolipoprotein E in traumatic brain injury as determined by isoform and Abca1 haplodeficiency
    Emilie L. Castranio · 2018 · D-Scholarship@Pitt (University of Pittsburgh)
  85. METAPLASTICITY IN A MOUSE MODEL OF ALZHEIMER’S DISEASE AND POSSIBLE THERAPEUTIC INTERVENTIONS
    Andrea Megill · 2014
  86. Oxidative modification of vesicular transporters in an animal model of Alzheimer’s disease
    Ying Wang · 2015 · Mspace (University of Manitoba)
  87. Evidence that an HDAC2-targeted ASO persistently upregulates cortical acetylcholine and dopamine signaling via a CREB | Gs positive feedback loop
    Teresa Hinkle Sanders · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  88. Genetic and functional studies of genes involved in the pathogenesis of Alzheimer's disease
    Teemu Natunen · 2014 · UEF eRepo (University of Eastern Finland)
  89. Engineering Human Induced Pluripotent Stem Cells (HIPSCS) to Investigate the Contribution of the APOE Risk Allele to the Onset and Progression of Alzheimer’s Disease
    Nick Brookhouser · 2020 · UA Campus Repository (The University of Arizona)
  90. Human Ependymin Neurotrophic Factor Mimetic Increases Alzheimer’s Mice Cognitive Performance in a Morris Water-Maze Test
    Tayeisha A. Jackson, Mortada Salman Najem · 2012 · Digital WPI
  91. Computational approaches to study drug resistance mechanisms
    Zoya Khalid · 2017 · Sabanci University
  92. Evaluación del potencial terapéutico de un extracto de raíz de Zanthoxylum caribaeum en un modelo triple transgénico de Enfermedad de Alzheimer
    Ruiz González, Juan Carlos · 2021
  93. REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR DETERMINATION OF BEXAROTENE IN CAPSULE DOSAGE FORM
    N Dhanvijay, Vijay Kumar Munipalli, M. Patel, S. Ghani, R. M Singh, Smita Nayak, Vaidhun H Bhaskar · 2018 · INDIAN DRUGS
  94. Krebsmittel gegen Alzheimer-Demenz?
    Kristina Endres · 2012 · InFo Neurologie + Psychiatrie
  95. Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkankungen, 9. Auflage
    2013 · Elsevier eBooks
  96. Apolipoprotein E
    Minerva M. Carrasquillo, Guojun Bu, Henrietta M. Nielsen · 2013 · Springer eBooks
  97. Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage
    2014 · Elsevier eBooks
  98. Targeting apolipoprotein E improves AD phenotype in mice
    2012 · Nature Reviews Neurology
  99. Additional file 2 of Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice
    Angie C.A. Chiang, Alexandre V. Seua, Pooja Singhmar, Luis D. Arroyo, Rajasekaran Mahalingam, JIAN LI HU, Annemieke Kavelaars, Cobi J. Heijnen · 2020 · Figshare
  100. Cancer signaling pathways: targets and treatment
    Beere Vishnusai, Ravikant Sharma, Vipan Kumar Parihar, Nitesh Kumar · 2024 · Elsevier eBooks